Combocef Tablet

Introduction

Combocef Tablet 200 mg+125 mg is a combination medication used to treat a variety of bacterial infections. Cefpodoxime Proxetil is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis, while Clavulanic Acid is a beta-lactamase inhibitor that helps prevent the breakdown of cefpodoxime by bacterial enzymes, enhancing its effectiveness against resistant strains.

Uses

This combination is used for treating infections such as:

Respiratory tract infections (e.g., pneumonia, bronchitis)
Urinary tract infections
Skin and soft tissue infections
Sinusitis

It is particularly effective in infections where beta-lactamase-producing bacteria may be present.

Brand Name	Combocef
Type	Tablet
Weight	200 mg+125 mg
Generic	Cefpodoxime Proxetil + Clavulanic Acid
Manufacturer	ACI Limited
Available in	English বাংলা

Mechanism of Action

Cefpodoxime Proxetil works by binding to penicillin-binding proteins (PBPs) in bacterial cell walls, inhibiting cell wall synthesis, which leads to bacterial cell death. Clavulanic Acid inhibits beta-lactamase enzymes produced by bacteria that would otherwise destroy cefpodoxime, thereby extending its spectrum of activity and making it effective against a broader range of bacteria.

How Long Does It Take to Work?

Improvements in symptoms are often seen within 48-72 hours of starting treatment. Full resolution of symptoms may take a few days longer, depending on the severity of the infection and the patient's response to the medication.

Absorption

Cefpodoxime Proxetil is absorbed from the gastrointestinal tract and is converted to its active form, cefpodoxime, after absorption. The presence of Clavulanic Acid does not significantly alter the absorption of cefpodoxime. The bioavailability of cefpodoxime is approximately 50% when administered orally.

Route of Elimination

Cefpodoxime is primarily eliminated through the urine, with about 50-70% of the dose excreted as unchanged drug. Clavulanic Acid is also excreted primarily through the urine, with a significant portion of the dose being eliminated as unchanged drug.

Dosage

For adults (Age 12 years and older):

Acute bacterial exacerbation of chronic bronchitis: 1 tablet 12 hourly for 10 days
Acute community acquired pneumonia: 1 tablet 12 hourly for 14 days
Pharyngitis or tonsillitis: ½ tablet 12 hourly for 5 to 10 days
Skin and soft tissue infections: 2 tablet 12 hourly for 7 to 14 days
Urinary tract infections: ½ tablet 12 hourly for 7 days
Uncomplicated gonorrhea: Single dose
Acute maxillary sinusitis: 1 tablet 12 hourly for 10 days

For children: Children 2 months to 12 years- 10 mg/kg/day in divided dose, every 12 hours.

The dosage of Combocef Tablet 200 mg+125 mg varies based on the type and severity of the infection, as well as the patient’s age and renal function. Typical dosing regimens include:

Adults: 200-400 mg of Cefpodoxime Proxetil and 125-250 mg of Clavulanic Acid every 12 hours.
Children: Dosage should be adjusted based on body weight and specific infection.

The exact dosage should be prescribed by a healthcare provider.

Administration

The medication is usually taken orally, with or without food. It is important to follow the prescribed dosing schedule and to complete the entire course of therapy to ensure the infection is fully eradicated.

Side Effects

Common side effects may include:

Nausea and vomiting
Diarrhea
Abdominal pain
Headache

Serious side effects, although less common, can include severe allergic reactions, liver enzyme abnormalities, or pseudomembranous colitis.

Toxicity

In cases of overdose or severe toxicity, symptoms may include gastrointestinal disturbances, renal impairment, and central nervous system effects such as seizures. Immediate medical attention is required in such cases.

Precautions

Precautions include:

Monitor for signs of allergic reactions, especially in patients with a history of penicillin or cephalosporin allergies.
Use with caution in patients with renal impairment, as dosage adjustments may be necessary.
Monitor for signs of gastrointestinal issues, including severe diarrhea or colitis.

Regular monitoring and follow-up with a healthcare provider are recommended during treatment.

Interaction

Combocef Tablet 200 mg+125 mg may interact with other medications, including:

Anticoagulants (e.g., warfarin) - may increase bleeding risk.
Other antibiotics - potential for altered efficacy or increased risk of side effects.
Probenecid - may increase levels of cefpodoxime in the blood.

Inform the healthcare provider of all medications being taken to avoid potential interactions.

Disease Interaction

Use with caution in patients with:

Renal impairment - dose adjustments may be needed.
Gastrointestinal conditions - may exacerbate conditions like colitis.

Regular monitoring and dose adjustments may be required based on disease status.

Drug Interaction

Drug interactions may include:

Antacids or iron supplements - may reduce the absorption of cefpodoxime.
Live vaccines - reduced effectiveness when used concurrently with antibiotics.

Consult a healthcare provider for guidance on managing potential drug interactions.

Food Interactions

Food interactions are minimal, but taking the medication with food may help reduce gastrointestinal discomfort. Avoiding high-fat meals may help optimize absorption.

Pregnancy Use

The use of Combocef Tablet 200 mg+125 mg during pregnancy should be based on a risk-benefit assessment by a healthcare provider. It is generally considered safe when prescribed for a specific infection, but caution is advised.

Lactation Use

Combocef Tablet 200 mg+125 mg is excreted in breast milk in small amounts. It is usually considered safe for use during lactation, but the healthcare provider should be informed of the medication to monitor for potential effects on the infant.

Acute Overdose

In the event of an acute overdose, symptoms may include gastrointestinal distress, renal impairment, or central nervous system effects. Immediate medical attention is necessary for appropriate management and treatment.

Contraindication

Contraindications include:

Known hypersensitivity to cefpodoxime, clavulanic acid, or any other component of the medication.
Severe renal impairment (with appropriate adjustments or alternative treatments based on healthcare provider guidance).

Avoid use in these cases to prevent adverse effects and ensure patient safety.

Use Direction

Follow the prescribed dosage and administration instructions carefully. Do not skip doses or discontinue the medication prematurely. If a dose is missed, take it as soon as remembered, but skip it if the next dose is approaching. Do not double the dose to make up for missed doses.

Storage Conditions

Store Combocef Tablet 200 mg+125 mg at room temperature, away from direct sunlight and moisture. Keep out of reach of children and ensure the container is tightly closed.

Volume of Distribution

The volume of distribution of cefpodoxime is approximately 0.3 L/kg, indicating moderate tissue distribution. Clavulanic acid has a similar volume of distribution, allowing effective distribution in body tissues and fluids.

Half Life

The half-life of cefpodoxime is approximately 2.4 hours, while the half-life of clavulanic acid is approximately 1 hour. These pharmacokinetic properties support effective dosing intervals.

Clearance

Both cefpodoxime and clavulanic acid are primarily cleared through the kidneys. The clearance rates may be reduced in patients with renal impairment, requiring dosage adjustments to avoid accumulation and toxicity.

See in details version Combocef Tablet 200 mg+125 mg also Combocef Tablet 200 mg+125 mg in bangla